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Abbreviations 34 
BMI – Body mass index 35 
cTnI  - cardiac troponin I 36 
cTnT - cardiac troponin T  37 
GS:SFHS – Generation Scotland Scottish Family Health Study 38 
SIMD - Scottish Index of Multiple Deprivation  39 
40 
3 
 
ABSTRACT  41 
Background 42 
Few data compare cardiac troponin T (cTnT) and troponin I (cTnI) in a general population. 43 
We sought evaluate the distribution and association between cTnT, cTnI, and cardiovascular 44 
risk factors in a large general population cohort. 45 
Methods 46 
High-sensitivity cTnT and cTnI were measured in serum from 19,501 individuals in the 47 
Generation Scotland Scottish Family Health Study. Associations with cardiovascular risk 48 
factors were compared using age and sex adjusted regression. Observed age- and sex-49 
stratified 99th centiles were compared to 99th centiles for cTnT (men 15.5ng/L, women 50 
9.0ng/L) and cTnI (men 34.2ng/L, women 15.6ng/L) used in clinical practice. 51 
Results  52 
cTnT and cTnI concentrations were detectable in 53.3% and 74.8% of participants 53 
respectively and were modestly correlated in unadjusted analyses (R2=21.3%), and only 54 
weakly correlated after adjusting for age and sex (R2=9.5%).  Cardiovascular risk factors 55 
were associated with both troponins, but in age and sex adjusted analyses cTnI was more 56 
strongly associated with age, male sex, BMI, and SBP (P<0.0001 for all versus cTnT). cTnT 57 
was more strongly associated with diabetes (P<0.0001 versus cTnI). The observed 99th 58 
centiles were broadly consistent with recommended 99th centiles in younger men and women. 59 
After the age of 60 years, observed 99th centiles increased substantially for cTnT, and beyond 60 
70 years of age, the 99th centiles approximately doubled for both troponins. 61 
Conclusions 62 
In the general population, cTnT and cTnI concentrations are weakly correlated and are 63 
differentially associated with cardiovascular risk factors.  99th centiles currently in use are 64 
broadly appropriate for men and women up to but not beyond the age of 60 years.  65 
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Introduction 67 
High sensitivity (hs) assays for the measurement of cardiac troponin T (cTnT) and troponin I 68 
(cTnI) are now used widely for the diagnosis of myocardial infarction. The universal 69 
definition of myocardial infarction recommends the 99th centile derived from a normal 70 
reference population be used to define myocardial necrosis. However, it is also increasingly 71 
apparent that troponin concentrations well below this threshold provide diagnostic and 72 
prognostic information in patients with both acute and stable cardiovascular diseases (1–3) 73 
and may have a role in screening the general population (1, 4).  74 
  The International Federation of Clinical Chemistry and Laboratory Medicine recently 75 
updated their guidance on the use of cardiac troponin testing and the criteria used to define a 76 
hs-cTn assay (5), which must have adequate precision (<10% coefficient of variation) at the 77 
99th centile and be able to measure cTn concentrations above the limit of detection in more 78 
than 50% of apparently healthy men and women. They also recommend at least 300 79 
participants in any age or sex specific strata to define the 99th centile for cardiac biomarkers 80 
(6). Several large studies have sought to independently validate the proportion of individuals 81 
with detectable cTn concentrations and the appropriateness of the 99th centile for these assays 82 
(7–10). However, few studies have measured both cTnI and cTnT in a single large general 83 
population cohort (11-12). 84 
 85 
Currently, the most frequently used high-sensitivity cardiac troponin assays include the 86 
Roche high sensitivity cardiac troponin T and the Abbott high sensitivity cardiac troponin I 87 
assay. As such, often the service provider to local biochemistry laboratories dictate whether 88 
cTnT or cTnI are measured in individual patients. Whether the performance of these assays, 89 
the mechanisms of cTnT and cTnI release into the circulation and subsequent clearance, and 90 
their associations with known cardiovascular risk factors are similar is unknown. Using these 91 
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clinically available high sensitivity assays, we measured both cTnT and cTnI in the 92 
Generation Scotland Scottish Family Health Study (GS:SFHS), a large general population 93 
cohort. The aim was to understand the relationship between cTnT and cTnI and how this is 94 
influenced by age, sex, and cardiovascular risk factors, and to evaluate how these factors 95 
influence the proportion of the population with detectable cTn concentrations and the 99th 96 
centile. 97 
 98 
Methods 99 
GS:SFHS  100 
The recruitment and design of the study has been reported in detail elsewhere (6). In brief, 101 
during 2006-2010 potential participants were identified at random from those aged 35–65 102 
years from the lists of collaborating general medical practices in Scotland, and invited to 103 
participate.  Participants were also asked to identify one or more first-degree relatives 18 104 
years or older who would be able to participate. A total of 21,476 participants aged between 105 
18 and 98 years attended a research clinic in either Glasgow, Dundee, Perth, Aberdeen or 106 
Kilmarnock, Scotland. Participants completed a health questionnaire, and had physical and 107 
clinical characteristics (including systolic blood pressure [SBP]and body mass index [BMI]) 108 
measured according to a standardized protocol (https://www.ed.ac.uk/generation-109 
scotland/using-resources/scottish-family-health-study).  Past medical history, including a 110 
diagnosis of diabetes mellitus (type 1 or type 2) and cardiovascular disease (prior myocardial 111 
infarction or stroke), was recorded using a self-reported questionnaire. Fasting blood samples 112 
were taken, according to a standard operating procedure, and serum samples were separated. 113 
Baseline biochemistry measures including total cholesterol, HDL cholesterol, and creatinine 114 
were generated at time of collection and additional serum aliquots were stored at -80oC for 115 
future biochemical analyses. Scottish Index of Multiple Deprivation (SIMD) scores are 116 
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national composite measures of deprivation, and are derived from participant postcodes (13). 117 
A composite 10 year cardiovascular risk score was also calculated in participants aged 35y or 118 
higher with no prevalent cardiovascular disease, based on the Scottish ASSIGN score used in 119 
clinical practice (14, 15) 120 
 121 
Measurement of hs-cTn 122 
hs- cTnT (Roche Diagnostics) and hs- cTnI (ARCHITECT STAT, Abbott Diagnostics) were 123 
measured on Cobas e411 and i1000SR analysers respectively. Both assays were calibrated 124 
and quality controlled using the manufacturer’s reagents. Coefficients of variation for cTnI 125 
were 6.2 % for the low control, 6.0% for intermediate control, and 4.6% for high control. 126 
Coefficients of variation for cTnT were 5.0% for the low control and 3.4% for the high 127 
control. We also participated in the National External Quality Assurance Scheme (NEQAS: 128 
https://ukneqas.org.uk/) for these biomarkers during the conduct of study. Some 129 
recommendations suggest that troponin results should be reported as whole numbers in an 130 
acute clinical setting, partly to reduce the risk of transcription errors. In this study, given the 131 
generally low troponin levels in a broadly healthy cohort, and in line with a substantial 132 
proportion of published literature, we report results to one decimal place. The limit of 133 
detection (LoD) of the cTnT assay is set to 3.0ng/L by the manufacturer, while we reported 134 
anything less than 1.2ng/L for cTnI as below the limit of detection (16). Results below the 135 
LoD are reported as half of the limit of detection (i.e. 1.5ng/L for cTnT and 0.6ng/L for cTnI) 136 
for continuous analyses.  The manufacturers report a 99th centile of 14.0 ng/L for cTnT, and 137 
26.2 ng/L for cTnI.  In addition there are sex specific 99th centiles defined for both assays (5): 138 
cTnT, 9.0 ng/L in women, 15.5 ng/L in men (10); cTnI, women 15.6 ng/L, men 34.2 ng/L 139 
(17, 18). A standard operating procedure was developed to facilitate measurement of both 140 
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troponin assays in tandem during a single (first) thaw of stored serum aliquots. Stored 141 
aliquots were spun at 2000g for 5 minutes before assay.  142 
 143 
Statistical analysis 144 
By clustered family group, the intra-class correlation coefficient was 0.18 (95%CI 0.16, 0.19) 145 
for cTnT and 0.09 (95%CI 0.07, 0.10) for cTnI, indicating minimal impact of family 146 
clustering on these analyses. Familial clustering was therefore not considered a factor in 147 
further analyses. Missing data for classical risk factors (1,134 missing observations for SIMD 148 
score was most frequently missing, no missing observations for age or sex) were imputed by 149 
multiple chained imputations over ten datasets; these were used for all analysis with classical 150 
risk factors.  151 
 152 
Associations of classical cardiovascular disease risk factors with external sex-specific 153 
elevated (>99th centile) troponins were illustrated, using categorical variables expressed as 154 
frequencies and percentages, and continuous variables as medians (inter quartile range) or 155 
mean (standard deviation). Differences between these categorized troponin groups were 156 
tested using chi-squared, rank sum test, or t-test respectively.  Associations of continuous 157 
classical risk factors and the cardiovascular disease risk score with log-transformed 158 
distributions of both troponins were tested using univariable linear regression with robust 159 
standard errors, and also using a multivariable (age and sex adjusted) approach for each 160 
troponin. Effect estimates were exponentiated to give the percentage effect on geometric 161 
mean troponin. The relationship between cTnT and cTnI was illustrated using scatter plots, 162 
and linear regression on z-scores from log-transformed troponin concentrations. The 163 
weighted Kappa statistic was used to test agreement between cTnT and cTnI by approximate 164 
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tertiles (with the lowest tertile for cTnT being results below the LoD, and the lowest tertile 165 
for cTnI forced to have approximately the same corresponding proportion of the cohort).  166 
 167 
The sex stratified GS:SFHS cTnT and cTnI 99th centiles along with associated bias corrected 168 
90% confidence intervals (as recommended by CLSI document C28-A3) around the 169 
estimates were determined by bootstrapping 5000 samples in each age and sex specific strata.  170 
The method was repeated in those with no cardiovascular disease. Two sensitivity analyses 171 
were conducted; the first removed those with log transformed troponin concentrations >5 172 
standard deviations from the mean, and the second used a rank model to obtain the GS:SFHS 173 
99th centile, and its associated 90% CI from a binomial distribution. We also performed 174 
quantile regression using fractional polynomials to model the relationship between age and 175 
99th centile of each troponin (supplement). All statistics were performed using STATA 176 
version 14.2. 177 
 178 
Results 179 
Population characteristics  180 
Of the 21,476 GS:SFHS participants, 19,501 participants provided a serum sample and 181 
yielded a measurement for both cTn assays (90.8%).  The median cTnT in the cohort was 182 
3.3ng/L (IQR 1.5, 6.0) and the median cTnI was 1.9ng/L (IQR 0.6, 3.1).  Detectable 183 
concentrations of cTnT and TnI were found in 10,395 participants (53.3%), and 14,579 184 
(74.8%) respectively. Women and younger individuals were more likely to demonstrate 185 
undetectable concentrations of troponin (Fig 1). At least 50% of men in each age stratum had 186 
detectable cTnT and cTnI.  More than 50% of women in ≤50-59 age groups had undetectable 187 
cTnT, and more than 50% of women in the ≤30-39 age group had undetectable cTnI (Fig 1).  188 
 189 
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Relationship between cTnT and cTnI 190 
A scatter graph illustrates a modest relationship between cTnT and cTnI (Fig 2). Using linear 191 
regression, the beta-coefficient for z-scores of log cTnI and log cTnT was 0.46 (95%CI 0.45, 192 
0.47) and the R2 was 21.3% (online Supplemental Fig s1). After adjusting for age and sex, 193 
the R2 between cTnT and cTnI was 9.5%. After excluding those with undetectable levels of 194 
either troponin and adjusting for age and sex, the R2 between cTnT and cTnI was 12.8% in 195 
the remaining 8,855 individuals. 196 
 197 
Comparing the distribution of tertiles for cTnT and cTnI, the expected agreement based on 198 
chance alone was 55.7%, but actual agreement was 70.8% (weighted kappa=0.34). Using the 199 
non-sex specific recommended 99th centile to categorize low and high cTn values, the 200 
expected agreement was 96.2%, and the observed agreement was 96.9% (kappa=0.19). 201 
 202 
Associations of troponin above the recommended 99th centiles with cardiovascular risk 203 
factors  204 
There were 296 male participants (3.6%) and 897 female participants (7.9%) with a cTnT 205 
result above the recommended 99th centile (15.5ng/L and 9.0ng/L, respectively). These 206 
participants were older, had a higher BMI, higher systolic blood pressure, higher serum 207 
creatinine, more frequently had a history of cardiovascular disease or diabetes, and more 208 
often used blood pressure or cholesterol medications in both sexes (Table 1). They also had 209 
lower total cholesterol concentrations among men only, had higher HDL-cholesterol 210 
concentrations among women only, and were less frequently current smokers in both sexes 211 
(Table 1).  212 
 213 
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For cTnI, 83 male participants (1.0%) and 115 female participants (1.0%) were above the 214 
recommended 99th centile (34.2ng/L and 15.6ng/L, respectively). Increased cTnI was 215 
associated with older age, higher systolic blood pressure, history of cardiovascular disease, 216 
and use of blood pressure or cholesterol medications in both sexes (Table 1). There was also 217 
an inverse association with current smoking in both sexes. However, high cTnI was not 218 
associated with BMI, total cholesterol or HDL-cholesterol in either sex (Table 1). 219 
 220 
Continuous associations of troponins with cardiovascular risk factors 221 
While cardiovascular risk factors were generally associated with both troponin measures, in 222 
age and sex adjusted analyses, stronger positive associations were found for cTnI with age, 223 
male sex, BMI, and SBP (P<0.0001 for all versus cTnT) (Table 2). cTnT was more strongly 224 
positively associated with diabetes, was inversely associated with total cholesterol, and 225 
positively associated with HDL-cholesterol (P<0.0001 versus cTnI) (Table 2). Both 226 
troponins had similar positive associations with prevalent cardiovascular disease, use of 227 
blood pressure lowering and cholesterol lowering medications and creatinine, and had no 228 
association with the Scottish Index of Multiple Deprivation. Both troponins were strongly 229 
inversely associated with current smoking (Table 2). Sensitivity analysis removing those 230 
with cardiovascular disease, diabetes, taking cholesterol lowering or blood pressure 231 
medications yielded broadly consistent results, although cTnI became more strongly 232 
associated with creatinine (P=0.001 versus cTnT) (online Supplemental Table s1).  A 233 
composite 10 year cardiovascular disease risk score calculated in participants without 234 
prevalent cardiovascular disease ≥35 years yielded similar positive associations with both 235 
cTnT and cTnI (p=0.34 comparing association with cTnT and cTnI) (Table 2). 236 
 237 
 238 
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GS:SFHS 99th centiles stratified by age and sex 239 
The 99th centiles stratified by age and sex were determined in the GS:SFHS and compared to 240 
the  recommended 99th centile (Fig 3). 241 
 242 
The observed 99th centile for cTnT was 21.4ng/L for men under 30 years, 15.4ng/L at 30-39 243 
years, 16.3ng/L at 40-49 years, 20.4ng/L at 50-59 years, 25.2ng/L at 60-69 years, and 244 
47.1ng/L at 70 years and over (Fig 3, online Supplemental Table s2). As such, the observed 245 
99th centile was approximately double the recommended 99th centile in men aged 60-69, and 246 
triple in men aged 70 years and over. Among men aged 60-69 and 70 years and over, 5.7% 247 
(95%CI 4.6, 7.0%) and 27.9% (95%CI 23.6, 32.5%) respectively had a cTnT value above the 248 
99th centile used in clinical practice (Fig 1).  249 
 250 
The corresponding age-group specific observed 99th centiles for women were 10.7ng/L, 251 
11.2ng/L, 12.4ng/L, 13.7ng/L, 18.9ng/L, and 38.6 ng/L. As such, the observed 99th centile 252 
was also approximately double the recommended 99th centile in women aged 60-69, and 253 
triple in women aged over 70 years (Fig 3, online Supplemental Table s2).   Among women 254 
aged 60-69 and 70 years and over, 10.1% (95%CI 8.8, 11.5%) and 39.1% (95%CI 35.3, 255 
43.0%) respectively had a cTnT value above the recommended 99th centile (Fig 1).  256 
 257 
The observed 99th centile for cTnI was 34.4ng/L for men under 30 years, 22.9ng/L at 30-39 258 
years, 30.4ng/L at 40-49 years, 27.0ng/L at 50-59 years, 42.9ng/L at 60-69 years, and 259 
86.2ng/L in those 70 years and over (Fig 3, online Supplemental Table s2). As such, the 260 
observed 99th centile was approximately double the recommended 99th centile in men aged 70 261 
years and over. Among men aged 60-69 years and 70 years and over 1.6% (95%CI 1.0, 2.3%) 262 
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and 2.6% (95%CI 1.3, 4.6%) respectively had a cTnI value above the recommended 99th 263 
centile (Fig 1).  264 
 265 
The corresponding observed age-group specific 99th centiles in women were 9.3ng/L, 266 
8.7ng/L, 12.5ng/L, 16.9ng/L, 17.4ng/L, and 39.2ng/L. As such, the observed 99th centile was 267 
also approximately double the recommended 99th centile in women over 70 years (Fig 3, 268 
online Supplemental Table s2).   Among women aged 60-69 years and 70 years and over, 269 
1.6% (95%CI 1.1, 2.2%) and 3.3% (95%CI 2.1, 5.0%) respectively had a cTnI value above 270 
the recommended 99th centile (Fig 1).  271 
 272 
Excluding those with cardiovascular disease had limited impact on the 99th centile for men or 273 
women for either assay (Fig 3, online Supplemental Table s2). For both cTnT and cTnI, 274 
excluding participants with outlying troponin values had little impact on estimates (online 275 
Supplemental Table s3). Further, using a rank model had little impact on the estimated 99th 276 
centiles (online Supplemental Table s4). Using a continuous model confirmed, and more 277 
finely modelled, the effect of older age on 99th centiles of both troponins (online 278 
Supplemental Figure s2). 279 
 280 
Discussion 281 
We report several important findings that are relevant to clinical practice, and the potential 282 
future use of troponin in CVD risk prediction. First, just over half of participants had 283 
detectable concentrations of cTnT whereas three quarters had detectable concentrations of 284 
cTnI. Troponin was undetectable in the majority of younger women. Second, there was a 285 
surprisingly weak association between cTnT and cTnI, particularly after taking into account 286 
the fact that both are higher in older people and in men. This expands on previous work 287 
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suggesting the 99th centiles are not biologically equivalent for the two troponins. Third, we 288 
observed important differences in the associations of cardiovascular disease risk factors with 289 
cTnT and cTnI respectively, although they had similar associations with a composite 290 
cardiovascular disease risk score overall. Therefore, these assays may be capturing distinct 291 
predictive information in the general population. Finally, the 99th centiles recommended for 292 
use in clinical practice, particularly for cTnT, may not be appropriate in older persons. This 293 
could lead to over-diagnosis of myocardial infarction and more referrals for further clinical 294 
investigation if troponin is used as a screening tool in the general population.  These findings 295 
may inform the selection of cTnT or cTnI tests for both diagnosis and cardiovascular risk 296 
screening.  297 
 298 
Since the cardiac troponin heterotrimer exists as a complex in the same cardiomyocytes (19), 299 
the modest inter-relationship of cTnT and cTnI, and their distinct associations with risk 300 
factors for myocardial damage, may be viewed as somewhat surprising. Previous reports 301 
demonstrate that they have distinct release kinetics in the acute setting; cTnI peaks earlier 302 
following MI (20). In addition, following intense aerobic exercise, both cTnT and cTnI 303 
increase, although it appears cTnI may continue to rise at least 5 hours after exercise, whereas 304 
cTnT plateaus earlier (21). There is therefore evidence that kinetics of release of troponins 305 
into the blood stream may explain at least part of the differences between cTnT and cTnI in 306 
our study. Although a recent study level meta-analysis suggested similar associations of cTnT 307 
and cTnI with CVD risk (P for interaction=0.027 suggesting that cTnT may be more strongly 308 
associated with risk) (4), our work comparing the two markers within individuals suggests 309 
that differences between studies might bias this comparison. Further work is required to 310 
investigate the distinct causal determinants of increased circulating troponins in the general 311 
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population as well as to identify the comparative (and combined) clinical utility of cTnT and 312 
cTnI in cardiovascular disease risk prediction in the general adult population. 313 
 314 
The slight increase in cTnT and cTnI in young (age 18-29) men compared to men in their 30s 315 
and 40s is also potentially surprising. However, troponins are influenced by left ventricular 316 
mass, which is likely to be higher in young men (22, 23). The inverse association of both 317 
cTnT and cTnI with current smoking that we report is consistent with data from the HUNT 318 
study, which reported that cTnI was inversely associated with smoking after adjustment for 319 
multiple potential confounding variables. (24) Data from the ARIC study raise a more 320 
complex picture for cTnT, reporting a weak inverse association between cTnT and current 321 
smoking, but a positive association with the number of pack-years. (25) Our data also show 322 
an inverse association of cTnT, but not cTnI, with total cholesterol. Similar data for cTnT has 323 
been previously reported in the older men from the British Regional Heart Study, although a 324 
positive association was observed in younger participants from the MIDSPAN family study 325 
(26). The positive association of cTnI with total cholesterol appears more consistent; indeed, 326 
it has been demonstrated in a randomized controlled trial that statin treatment rapidly causes 327 
decline in cTnI (1).  328 
 329 
Our results also highlight that although the recommended 99th centiles for cTnT and cTnI 330 
(16) fit generally well with GS:SFHS results for those aged <60 years, such cut-offs are much 331 
higher beyond the age of 60 years for cTnT, and beyond the age of 70 for cTnI. For instance, 332 
fully a third of men over the age of 70 had a cTnT above the predefined 99th centile of 333 
15.5ng/L. In elderly people, increased troponin concentrations may reflect subclinical 334 
myocardial injury (27). If troponin is to be utilized for population level cardiovascular disease 335 
risk screening, this means older patients will be more frequently identified with increased 336 
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troponins on screening, and will be more likely to be referred for further cardiovascular 337 
testing such as echocardiography or coronary angiography. This may be entirely appropriate 338 
as raised troponin in this group may well reflect undiagnosed structural or coronary heart 339 
disease (28). Clinicians therefore need to be aware of the effect of age on troponin reference 340 
concentrations, and further evaluation of the 99th centile, or biological equivalents, in older 341 
patients with chest pain would be welcome. Use of serial testing of troponin may be helpful 342 
to demonstrate myocardial injury is chronic in an individual.  343 
 344 
Strengths of this study include the ability to directly compare cTnT and cTnI in the general 345 
population as well as the large size, and wide age range, which allows stratified analysis of 346 
the 99th centiles with sufficient power in most strata according to guidelines (6). Both 347 
troponins were measured using assays comparable to most clinical biochemistry departments. 348 
Weaknesses include the family structure of GS:SFHS , although we demonstrate this had 349 
little impact on data in terms of clustering within families. A large proportion of participants 350 
had undetectable troponin. This is suboptimal for continuous statistical analyses, but is an 351 
important feature in describing the utility of the measurements in the general population. 352 
Analyses are cross-sectional and thus we can only comment on the general trends of 353 
associations with risk factors with troponin concentrations without causal inferences. The 99th 354 
centiles for cTnT and cTnI are not biological equivalents (29,30); they are observational 355 
cutoffs taken from distinct populations. Direct comparison of the differences between the 356 
troponins based only on the cutoffs may therefore be misleading, although continuous models 357 
support our analyses as well. 358 
 359 
In conclusion, in a large cohort study from a general population, cTnT and cTnI 360 
concentrations are differentially associated with cardiovascular risk factors and are weakly 361 
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correlated with each other. Existing sex specific 99th centiles are broadly appropriate for both 362 
men and women up to the age of 60 years. Beyond the age of 70, the 99th centile is 363 
approximately 3-fold higher for cTnT in both men and women and 2-fold higher for cTnI in 364 
women. 365 
 366 
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Figure Legends 474 
Figure 1  475 
Age and sex stratified percentage of participants with undetectable cTnT (<3ng/L) and cTnI 476 
(<1.2ng/L) in upper panels (red), and percentage of participants above the recommended 99th 477 
centile for cTnT and cTnI in lower panels (green). 478 
Figure 2  479 
Illustrative scatter graph of the distributions of cTnT and cTnI, with red dotted line indicating 480 
the recommended (non-sex specific) 99th centile (n=19,501). Results below the LoD are 481 
reported as half of the limit of detection (i.e. 1.5ng/L for cTnT and 0.6ng/L for cTnI).  Axes 482 
are on Log2 scale. 483 
Figure 3  484 
Age and sex stratified predicted troponin 99th centiles within GS:SFHS (with 90% CI), with 485 
sensitivity analysis excluding those with cardiovascular disease. Black dotted line indicates 486 
the non-sex specific recommended 99th centile, red dotted line indicates the recommended 487 
99th centile for women only, blue dotted line the 99th centile for men only. 488 
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Table 1 Population characteristics among men, stratified by status above or below the recommended sex specific 99th centile of cTnT and cTnI 
   hs-cTnT  hs-cTnI 
 Women 
<9ng/L 
Women 
≥9ng/L 
P-value  Men 
<15.5ng/L 
Men 
≥15.5ng/L 
P-value  Women 
<15.6ng/L 
Women 
≥15.6ng/L 
P-value  Men  
<34.2ng/L 
Men 
≥34.2ng/L 
P-value 
  n=10478 n=897   n=7830 n=296   n=11260 n=115   n=8043 n=83  
Age 46.2±14.2 59.4±15.8 0.0001  46.3±14.8 61.8±17.2 <0.0001  47.1±14.8 56.9±15.8 0.0001  46.8±15.2 51.1±17.7 0.0098 
Body mass 
index (kg/M2) 
26.4±5.6 27.3±5.7 <0.0001  26.8±4.5 28.2±5.1 <0.0001  26.5±5.6 26.5±5.8 0.955  26.9±4.5 27.4±5 0.2692 
Systolic blood 
pressure 
(mmHg) 
127.2±17.8 137.4±21.4 <0.0001  135.9±15.7 142.0±20.5 <0.0001  127.9±18.2 138.4±23.4 <0.0001  136.0±15.9 141.8±17.8 0.0064 
Total 
cholesterol 
(mg/dl) 
200±42 201±44 0.6167  194±41 177±40 <0.0001  200±42 200±45 0.969  194±41 187±42 0.132 
HDL-
cholesterol 
(mg/dl) 
61±16 63±18 0.0004  50±13 50±15 0.762  61±16 62±15 0.6536  50±13 48±13 0.0907 
SIMD score  12 (7,24) 12 (7,25) 0.3336  11 [7, 21] 11 [6,19] 0.445  12 (7,24) 12 (8,25) 0.586  11 [7, 21] 11 [7, 21] 0.930 
Creatinine 
(mg/dl) 
0.73±0.12 0.79±0.30 <0.0001  0.91±0.15 1.06±0.36 <0.0001  0.74±14 0.78±19 0.0004  0.92±0.16 0.92±0.16 0.854 
Current smoker 1843 
(17.6%) 
119 
(13.3%) 
0.0010  1617 
(20.7%) 
29 
(9.8%) 
<0.0001  1955 
(17.4%) 
7 
(6.0%) 
0.0015  1639 
(20.4%) 
7 
(8.4%) 
0.0071 
Baseline heart 
disease or stroke 
287 
(2.7%) 
82 
(9.1%) 
<0.0001  444 
(5.7%) 
64 
(21.6%) 
<0.0001  355 
(3.2%) 
14 
(12.2%) 
<0.0001  495 (6.2%) 13 
(15.7%) 
0.0004 
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Data are mean ±standard deviation, median [interquartile range], or n (%). To convert total cholesterol and HDL cholesterol to mmol/l multiply 
by 0.02586. To convert creatinine to mol/L multiply by 88.4 
 
Baseline 
diabetes 
196 
(1.9%) 
60 
(6.7%) 
<0.0001  258 
(3.3%) 
48 
(16.2%) 
<0.0001  249 
(2.2%) 
7 
(6.1%) 
0.0053  302 (3.8%) 4 
(4.8%) 
0.6123 
Baseline use of 
cholesterol 
lowering 
medications 
488 
(4.7%) 
116 
(12.9%) 
<0.0001  609 
(7.8%) 
69 
(23.3%) 
<0.0001  591 
(5.2%) 
13 
(11.3%) 
0.004  661 (8.2%) 17 
(20.5%) 
<0.0001 
Baseline use of 
blood pressure 
lowering 
medications  
680 
(6.5%) 
152 
(16.9%) 
<0.0001  664 
(8.5%) 
78 
(26.4%) 
<0.0001  815 
(7.2%) 
17 
(14.8%) 
0.002  726 
(9%) 
16 
(19.3%) 
0.0013 
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Table 2 Univariable and age and sex adjusted association of cardiovascular disease risk 
factors with cTnT and cTnI (n=19,501). A positive percentage indicates a relative increase in 
troponin for a corresponding increase in the risk factor, while a negative percentage indicates 
an inverse association.  
 Univariable model  Age and sex adjusted model  
  cTnT cTnI  cTnT cTnI P-value 
comparing 
association with 
cTnT vs. cTnI 
Age (per 5 years) a 9.5% 
(9.2, 9.9) 
11.3% 
(10.9, 11.7) 
 9.6% 
(9.3, 10.0) 
11.4% 
(11.1, 11.8) 
<0.0001 
Male sex a 44.0% 
(41.8, 46.2) 
53.1% 
(50.7, 55.5) 
 44.7% 
(42.7, 46.8) 
54.0% 
(51.7, 56.2) 
<0.0001 
Body mass index (per 
kg/m2) 
1.5% 
(1.2, 1.7) 
2.8% 
(2.6, 3.1) 
 0.3% 
(0.0, 0.5) 
1.4% 
(1.2, 1.7) 
<0.0001 
Systolic blood 
pressure (per 5mmHg) 
5.7% 
(5.4, 6.1) 
8.6% 
(8.3, 9.0) 
 1.1% 
(0.8, 1.5) 
3.7% 
(3.3, 4.0) 
<0.0001 
Total cholesterol (per 
10mg/dl) 
-1.0% 
(-1.4, -0.7) 
1.0% 
(0.7, 1.4) 
 -1.7% 
(-2.0, -1.5) 
0.5% 
(0.2, 0.8) 
<0.0001 
HDL-cholesterol (per 
5mg/dl) 
-1.0% 
(-1.4, -0.6) 
-2.1% 
(-2.6, -1.7) 
 0.4% 
(0.0, 0.8) 
-0.3% 
(-0.7, 0.2) 
0.003 
SIMD score (per 10 
units) 
-2.4% 
(-3.2, -1.7) 
-2.0% 
(-2.9, -1.2) 
 -0.4% 
(-1.2, 0.3) 
0.4% 
(-0.4, 1.1) 
0.0486 
Creatinine (per 
0.1mg/dl) 
9.4% 
(8.3, 10.5) 
10.9% 
(9.5, 12.4) 
 2.7% 
(1.8, 3.6) 
3.3% 
(2.5, 4.1) 
0.239 
Current smoker -17.1% 
(-19.8, -14.3) 
-19.8% 
(-22.8, -16.8) 
 -10.6% 
(-13.2, -8.0) 
-12.0% 
(-14.8, -9.5) 
0.3331 
Baseline heart disease 
or stroke 
59.5% 
(53.7, 65.2) 
66.3% 
(60.0, 72.7) 
 22.6% 
(17.6, 27.6) 
22.2% 
(16.3, 28.0) 
0.8883 
Baseline diabetes 59.4% 
(52.1, 66.7) 
34.5% 
(26.6, 42.5) 
 32.7% 
(26.4, 39.0) 
2.1% 
(-4.9, 9.1) 
<0.0001 
Baseline use of 
cholesterol lowering 
medications 
57.2% 
(52.6, 61.8) 
61.1% 
(56.5, 65.7) 
 22.4% 
(18.1, 26.7) 
19.2% 
(14.8, 23.6) 
0.2178 
Baseline use of blood 
pressure lowering 
medications 
55.3% 
(51.1, 59.4) 
65.3% 
(61.2, 69.3) 
 25.2% 
(21.3, 29.0) 
29.4% 
(25.4, 33.3) 
0.0766 
Cardiovascular disease 
risk score (per 1% 
increase in 10 year 
risk) b 
2.8% 
(2.6, 2.9) 
2.7% 
(2.6, 2.9) 
 - - - 
a Age effect adjusted for sex, and sex effect adjusted for age b Composite cardiovascular 
disease risk score calculated in people without cardiovascular disease aged ≥35 years 
(n=14,257). 



